Muharrem Coşkunpınar

MD,
@AnkaraUni Medical Oncology Fellow 🦀🧬
@JCO_ASCO Reviewer Trainee

[Muharrem Coşkunpınar @mcpinar]

Happy to share that I’ve been accepted into the @JCO_ASCO Reviewer Trainee Program 🎉
We had our first meeting today.
Peer review is the backbone of scientific publishing. I hope to contribute to this essential process.Many thanks to @ASCO for this opportunity!
#JCO #PeerReview

[Emre Yekedüz @yekeduz_emre]

Join us for wrapping up latest updates in GU cancers shared at #ASCO26 ! #cancer #oncology 👇

[Conquer Cancer, the ASCO Foundation @ConquerCancerFd]

Two grantees on the same plenary stage, in two different cancers, on the same day. This is not luck. It is what happens when you identify exceptional scientists early, across every cancer type, and invest in them consistently. Read the announcement: https://t.co/PudsRLcx9i

#ASCO26 #ResearchConquersCancer #ConquerCancer

[Yüksel Ürün @DrYukselUrun]

Before a plenary changes practice, someone first believes in the scientist.
Early cancer research funding is not a grant.
It is a lifeline for future patients.
#ASCO26 @ASCO @ConquerCancerFd

[Emre Yekedüz @yekeduz_emre]

🎉Our very own @BbaharK presenting our study at #ASCO26! I am extremely happy for being the senior author for the first time!

In this real-world chrono-immunotherapy analysis, we used cluster analysis of ICI infusion timing up to 24 cycles for each patient and found that midday administration was associated with the longest overall survival in patients with metastatic cancer.

👉‼️Our translational study are on the way to better understand the biology behind these findings

#Immunotherapy #CancerResearch @DrYukselUrun @AnkaraUni @AUTF_DEKANLIK @OncoReporte @OncoAlert @OpenMedicineHQ @mert_karaoglann @realbowtiedoc

[Beliz Bahar Karaoğlan @BbaharK]

Excited to be presenting our poster at #ASCO2026📍Poster Board 145
Midday ICI Infusion Influence on Survival in Patients with Metastatic Cancer: A Real-World Chrono-Immunotherapy Study
Feel free to stop by and take a look! @yekeduz_emre @realbowtiedoc @crisbergerot @DrYukselUrun

[Yüksel Ürün @DrYukselUrun]

This is not simply a new pancreatic cancer drug.

It is a reminder that even “undruggable” biology can become treatable with persistence.

Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months.
A remarkable ASCO moment.
#ASCO26
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists

[Tom Powles @tompowles1]

Daraxonrasib (multi-selective RAS inhibitor) addresses one of the biggest challenges in oncology and beats chemotherapy in 2nd line advanced pancreas cancer, creating a pivotal moment. #ASCO26 @Annals_Oncology @OncoAlert @DrChoueiri

[Erman Akkus @Erman_Akkus]

📮My letter on neoadjuvant GOLP study in intrahepatic cholangiocarcinoma has been published in NEJM

🟦BILCAP cape arm: mRFS 24.3 mo

🟦ZSAB-neoGOLP control arm (surgery-cape): mEFS 8.7 mo

❓Is it unexpectedly short?

✅Thanks authors for the response and NEJM for giving this discussion opportunity.

👉https://t.co/DTb76O5Ule

#cancer #oncology #biliary #cholangiocarcinoma #MedX @OncoAlert @curecc @PrecisionBTCnet

[Dra. María Natalia Gandur Quiroga @nataliagandur]

⭐ Quality of life in mHSPC — how should it shape treatment decisions?
@OncoAlert @APCCC_Lugano #APCCC26 @Silke_Gillessen @AOmlin
Presented by @DrYukselUrun
🔹 Powerful and deeply human talk bringing patients back to the center of decision-making

🔹 Key insights:
• Treatments are improving → patients live longer
➡️ but those years must be lived well
• QoL is multidimensional:
→ physical
→ cognitive
→ emotional
→ social
• The “toxicity paradox”:
→ intensification may prolong survival
→ but cumulative toxicity can erode quality of life

• Frailty, comorbidities and social context are critical determinants
• PROs are essential → QoL should be measured, not assumed
🔹 What patients value most:
→ independence
→ energy
→ cognitive function
→ sexual health
🔹 Take-home:
Survival and QoL are not competing goals —
they must be integrated in every treatment decision
👏 Outstanding perspective — clinically and humanly essential
@LoebStacy @DrRanaMcKay @RenuEapen @Uromigos
@fabioturco92 @BertrandTOMBAL @DrSpratticus @LoebStacy @tompowles1 @Cdanicas @piet_ost @UrsulaVogl @EAntonarakis @DrRanaMcKay
#ProstateCancer #UroOncology #Oncology

[NEJM @NEJM]

In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905 trial results and Research Summary: https://t.co/bzVbmJXHMD

[Toni Choueiri, MD @DrChoueiri]

“To love someone else is easy, but to love what you are, the thing that is yourself, is just as if you were embracing a glowing red-hot iron: it burns into you and that is very painful. Therefore, to love somebody else in the first place is always an escape which we all hope for, and we all enjoy it when we are capable of it. But in the long run, it comes back on us. You cannot stay away from yourself forever, you have to return, have to come to that experiment, to know whether you really can love. That is the question-whether you can love yourself, and that will be the test”—Carl Jung (1875-1961)

[Muharrem Coşkunpınar @mcpinar]

Congrats again ! 👏👏@hatice_bolek

[ESMO - Eur. Oncology @myESMO]

📣 Validate your expertise with #ESMOExamination 2026 — 24 Oct, 13:00–15:30 CEST.

📍Onsite in Madrid + selected locations.
⏳Early fee ends 28 Apr.
🔗 Secure your seat: https://t.co/08KgVZwrbW

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Advancing Precision in Muscle-Invasive Bladder Cancer: The Critical Role of Histologic Subtyping

#ASCODailyNews @ASCO #OncSurgery @UTMDAnderson @SagarRPatelMD @TarynAEllis @JosephBBlack

https://t.co/BJogRg06Ho #EAU26

[ONCOassist® | The go-to oncology app @ONCOassist]

🎧 Expert Insights – New Episode

Dr. Yüksel Ürün breaks down key Genitourinary oncology studies from ASCO GU26, including:

• EV + Pembrolizumab in bladder cancer
• Belzutifan combinations in RCC
• PARP + ARPI in prostate cancer

🎙️ Watch the full episode: https://t.co/ssQPp5DXEy

#OncologySpotlight #ExpertInsights #CancerCare #OncologyPodcast #MedicalOncology #ONCOassist #Oncoalert #GU26 @DrYukselUrun @ASCO

[Yüksel Ürün @DrYukselUrun]

Staging of Bladder Cancer:
CT is accessible and fast for staging.

mpMRI with VI-RADS shows higher accuracy for muscle invasion and helps distinguish NMIBC vs MIBC.

Where expertise exists, MRI can strengthen bladder preservation strategies.
Access and standardization remain key challenges.

#gu26 #cancer #oncology #ASCO @oncoalert @ASCO @yekeduz_emre @CParkMD @OncBrothers @Larvol @nataliagandur @crisbergerot @ONCOassist @IMG_Oncologists

[Yüksel Ürün @DrYukselUrun]

Perioperative landscape in MIBC is shifting. @AndreaNecchi

Phase 3 trials integrate IO/chemo in neoadjuvant and adjuvant settings.

pCR rates with IO combinations, including EV+pembro, are reshaping expectations.
Now we need durable survival data.

#gu26 #cancer #oncology #ASCO @oncoalert @ASCO @yekeduz_emre @CParkMD @OncBrothers @Larvol @nataliagandur @crisbergerot @ONCOassist @IMG_Oncologists

[Yüksel Ürün @DrYukselUrun]

Response-adapted bladder preservation in MIBC:
Selecting the right patient is everything.

Q: How to define CCR? @AndreaNecchi

#gu26 #cancer #oncology #ASCO @oncoalert @ASCO @yekeduz_emre @CParkMD @OncBrothers @Larvol @nataliagandur @crisbergerot @ONCOassist @IMG_Oncologists @apolo_andrea

[Yüksel Ürün @DrYukselUrun]

Perioperative MIBC is entering a new era.
The question is no longer if.
It is which regimen, for which patient.
#gu26 #cancer #oncology #ASCO @oncoalert @ASCO @yekeduz_emre @CParkMD @OncBrothers @Larvol @nataliagandur @crisbergerot @ONCOassist @IMG_Oncologists

[Muharrem Coşkunpınar @mcpinar]

Muharrem Coşkunpınar: Expanding Perspectives in Metastatic Bladder and Kidney Cancer Care https://t.co/eahrXteD1Y

[Muharrem Coşkunpınar @mcpinar]

I am truly honored and delighted to have participated in the @myESMO Preceptorship on Metastatic Bladder and Kidney Cancer ✨

It was an inspiring experience to learn from world-leading experts in the field, gain insights into the latest advances, and
—most importantly—have the opportunity to meet them in person, exchange ideas, and engage in meaningful scientific discussions 🧠

I would like to express my sincere gratitude to @myESMO for organizing such an outstanding educational program that broadens perspectives, strengthens multidisciplinary thinking, and fosters international collaboration 🤝💪🏻
@AlbigesL @tompowles1 @myESMO
#oncology #bladder #kidney #cancer